Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.61 |
| ▸ | LPL | P06858 | 12/20 | 0.37 |
| ▸ | LIPG | Q9Y5X9 | 12/20 | 0.37 |
| ▸ | F11 | P03951 | 1/20 | 0.36 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.31 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1331340 | 0.87 | FFAR1 (0.61) | FFAR1LPLLIPGF11IRAK4 | |
| SCHEMBL1484925 | 0.85 | FFAR1 (0.60) | FFAR1LPLLIPGF11IRAK4 | |
| SCHEMBL21275456 | 0.85 | FFAR1 (0.60) | FFAR1LPLLIPGF11IRAK4 | |
| SCHEMBL13157050 | 0.85 | FFAR1 (0.60) | FFAR1LPLLIPGF11IRAK4 | |
| SCHEMBL2511129 | 0.85 | FFAR1 (0.60) | FFAR1LPLLIPGF11IRAK4 | |
| SCHEMBL20759 | 0.85 | FFAR1 (0.64) | FFAR1LPLLIPGF11IRAK4 | |
| SCHEMBL29808355 | 0.84 | FFAR1 (0.56) | FFAR1LPLLIPGF11IRAK4 | |
| SCHEMBL17247560 | 0.84 | FFAR1 (0.58) | FFAR1LPLLIPGF11IRAK4 | |
| SCHEMBL790905 | 0.83 | FFAR1 (0.65) | FFAR1LPLLIPGF11IRAK4 | |
| SCHEMBL253540 | 0.83 | FFAR1 (0.57) | FFAR1LPLLIPGIRAK4DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2646448-B1 | MACROCYCLIC KINASE INHIBITORS | OSI PHARMACEUTICALS LLC (US) | 2017-08-30 | — | — | EP | disclosed |
| US-9133224-B2 | Macrocyclic kinase inhibitors | OSI Pharmaceuticals, LLC (US) | 2015-09-15 | — | — | US | disclosed |
| EP-2646448-A1 | MACROCYCLIC KINASE INHIBITORS | OSI Pharmaceuticals, LLC (US) | 2013-10-09 | — | — | EP | disclosed |
| US-20130261086-A1 | MACROCYCLIC KINASE INHIBITORS | OSI Pharmaceuticals, LLC (US) | 2013-10-03 | — | — | US | disclosed |
| WO-2012074951-A1 | MACROCYCLIC KINASE INHIBITORS | OSI Pharmaceuticals, LLC (US) | 2012-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130261086-A1 | MACROCYCLIC KINASE INHIBITORS | PTK2, SRC, PTK2B | FFAR1 1692/4885LPL 4298/4885LIPG 3812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.